Reply

Affiliations

¹ University Eye Clinic, Maastricht University Medical Center, Maastricht, the Netherlands. Electronic address: henny.beckers@mumc.nl.
² CHU de Grenoble-Alpes, Grenoble, France.
³ University Eye Clinic, Maastricht University Medical Center, Maastricht, the Netherlands.
⁴ Hôpital Paris Saint Joseph, Paris, France.
⁵ Departamento de Oftalmologia Universidad Complutense, Hospital Clínico San Carlos, OFTARED, Madrid, Spain.
⁶ Pôle Ophtalmologique de la Clinique Mutualiste, Bordeaux, France.
⁷ Santen Inc, Emeryville, California.
⁸ InnFocus Inc, a Santen Company, Miami, Florida.
⁹ Hôpitaux Universitaires de Genève, Geneva, Switzerland.

Comment

Henny J M Beckers et al. Ophthalmol Glaucoma. 2022 Jan-Feb.

. 2022 Jan-Feb;5(1):e1-e2.

doi: 10.1016/j.ogla.2021.10.006. Epub 2021 Nov 17.

¹ University Eye Clinic, Maastricht University Medical Center, Maastricht, the Netherlands. Electronic address: henny.beckers@mumc.nl.
² CHU de Grenoble-Alpes, Grenoble, France.
³ University Eye Clinic, Maastricht University Medical Center, Maastricht, the Netherlands.
⁴ Hôpital Paris Saint Joseph, Paris, France.
⁵ Departamento de Oftalmologia Universidad Complutense, Hospital Clínico San Carlos, OFTARED, Madrid, Spain.
⁶ Pôle Ophtalmologique de la Clinique Mutualiste, Bordeaux, France.
⁷ Santen Inc, Emeryville, California.
⁸ InnFocus Inc, a Santen Company, Miami, Florida.
⁹ Hôpitaux Universitaires de Genève, Geneva, Switzerland.

No abstract available

Comment on

Safety and Effectiveness of the PRESERFLO® MicroShunt in Primary Open-Angle Glaucoma: Results from a 2-Year Multicenter Study.
Beckers HJM, Aptel F, Webers CAB, Bluwol E, Martínez-de-la-Casa JM, García-Feijoó J, Lachkar Y, Méndez-Hernández CD, Riss I, Shao H, Pinchuk L, Angeles R, Sadruddin O, Shaarawy TM. Beckers HJM, et al. Ophthalmol Glaucoma. 2022 Mar-Apr;5(2):195-209. doi: 10.1016/j.ogla.2021.07.008. Epub 2021 Jul 28. Ophthalmol Glaucoma. 2022. PMID: 34329772
Re: Beckers et al.: Safety and effectiveness of the PRESERFLO® MicroShunt in primary open-angle glaucoma: results from a 2-year multicenter study. Ophthalmol Glaucoma (2021;doi 10.1016/j.ogla.2021.07.008: Jul 28 [Epub ahead of print].).
Sherman TEJ, Yu-Wai-Man C, Goyal S, Lim KS. Sherman TEJ, et al. Ophthalmol Glaucoma. 2022 Jan-Feb;5(1):e1. doi: 10.1016/j.ogla.2021.10.007. Epub 2021 Nov 17. Ophthalmol Glaucoma. 2022. PMID: 34801439 No abstract available.